Dipraglurant is an oral, small molecule allosteric modulator with a potential to be used as combination therapy with levodopa or dopamine agonists or as a standalone treatment for PD-LID, PD-related motor symptoms, dystonia, non-motor symptoms of PD and other movement disorders.
The candidate works by inhibiting the metabotropic glutamate receptor 5 (mGluR5), a Class C G-Protein Coupled Receptor (GPCR) selectively.
The Michael J Fox Foundation chief executive officer Todd Sherer said, "Dipraglurant targets a molecular mechanism that our Foundation has been investing in since 2005 and we are pleased to take part in its continued progress to the clinic."
Addex chief executive officer Bharatt Chowrira said, "We believe the successful completion of the Phase 2a study offers some promise that dipraglurant has the potential to significantly change both the way patients are treated as well as their quality of life."